News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
127.08
+2.83 (+2.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 19, 2024
Via
Benzinga
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Via
Benzinga
Exposures
Product Safety
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 16, 2024
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.
Via
Benzinga
In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics
February 15, 2024
Via
Benzinga
Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
January 30, 2024
Via
Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
February 16, 2024
The biotech just scored a big FDA win with an even bigger one potentially coming by June.
Via
The Motley Fool
Exposures
Product Safety
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
February 16, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 16, 2024
Via
Benzinga
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
February 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
January 10, 2024
Via
Benzinga
2 Magnificent Growth Stocks to Buy With $500
February 15, 2024
No need to break the bank to invest in promising stocks.
Via
The Motley Fool
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
Via
Benzinga
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
February 11, 2024
Bad news for one player does not always equal good news for another.
Via
The Motley Fool
Decoding Bearish Analog And The Warning Signs You Can't Ignore
February 07, 2024
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
February 06, 2024
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy
Via
MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
January 29, 2024
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.
Via
Benzinga
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
January 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
MarketBeat Week in Review: 1/22 - 1/26
January 27, 2024
Markets continued to push to new all-time highs, setting the stage for big tech earnings, which will happen next week; here are the top stories from this week.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Got $3,000? 3 Growth Stocks to Double Up On Right Now
January 26, 2024
There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important.
Via
The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
It's always tough to be compared to a giant.
Via
The Motley Fool
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
Via
MarketBeat
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
January 22, 2024
One pundit feels there is solid potential in one of the company's more recently approved drugs.
Via
The Motley Fool
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
January 16, 2024
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.
Via
InvestorPlace
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
January 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
January 09, 2024
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
January 09, 2024
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product
Via
Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
January 09, 2024
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.